Skip to main content
Premium Trial:

Request an Annual Quote

But Does it Come With an iPhone?

AT&T, the US telecommunications company, is teaming up with National LambdaRail to connect researchers working in genomic medicine, reports Jennifer Dennard at HealthcareIT News. According to a press release, "AT&T will deliver high bandwidth connectivity to NLR's national network infrastructure," beginning with St. John's Health Center in Santa Monica, California. Geeta Nayyar, the chief medical information officer at AT&T ForHealth, tells Dennard that the goal is to connect biomedical institutes across the US so that physicians can better prevent and treat disease, with a particular focus on personalized medicine.

"There is an incredible amount of infrastructure involved in delivering modern healthcare. Though the effort may not seem as buzz-worthy as the flashier WellDoc/Alere/mobile health announcement, I wouldn’t wonder if this high bandwidth connectivity will actually enable more accelerated clinical transformation," Dennard writes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.